Rhode Island Medicaid and GLP-1s
Rhode Island named the four drugs it is dropping, gave a date, and said why: the enacted state budget. From October 1, 2026, Medicaid stops paying for Foundayo, Saxenda, Wegovy and Zepbound when the reason is weight loss. Everything else about them stays reachable, and the memo says how.
What changed, and what the document says
The date, and the reason
Not coveredThis isn't a clinical review. It's a budget instruction, and the memo leads with that.
“Pursuant to the Rhode Island State Fiscal Year 2027 Enacted Budget, beginning October 1, 2026, Rhode Island Medicaid will no longer cover certain GLP-1 receptor agonists when they are prescribed solely for weight loss.”
Rhode Island Executive Office of Health and Human Services — August 5, 2026
Which four
Not coveredNamed individually, which is rarer than it should be. Foundayo on the list makes this one of the first cuts to reach an oral GLP-1.
“Foundayo (Orforglipron)”
Rhode Island Executive Office of Health and Human Services — August 5, 2026
The word doing the work
Conditions applySolely. A different indication is a different question, and the memo keeps that door open.
“The medications that Rhode Island Medicaid will no longer cover when used solely for weight loss include:”
Rhode Island Executive Office of Health and Human Services — August 5, 2026
Keeping one of them
Conditions applyAn existing approval doesn't carry over. It's a fresh request with clinical records attached.
“If continued treatment with one of these medications listed above is medically necessary for an indication other than weight loss, providers must submit a new PA request with the appropriate clinical documentation.”
Rhode Island Executive Office of Health and Human Services — August 5, 2026
Under 21 is a separate track
CoveredThe federal child-health benefit still applies, and the memo says every one of those requests gets reviewed under it.
“For members younger than 21 years of age, all PA requests must be reviewed for medical necessity in accordance with Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) requirements.”
Rhode Island Executive Office of Health and Human Services — August 5, 2026
What's being taken away
ContextThe current list still runs a full obesity-drug class, with every product in it behind a human reviewer rather than a claims edit.
“Clinical Prior Authorization Required for Entire Class/Manual PA”
Rhode Island Executive Office of Health and Human Services — Updated: 6/16/2026
The class is three years old
ContextRhode Island stood this up in October 2023 and reviewed it in May 2026, four months before deciding to end it.
“Status Implementation: 10/03/2023”
Rhode Island Executive Office of Health and Human Services — Updated: 6/16/2026
The diabetes rule, unchanged
CoveredNothing in the memo touches this one. A GLP-1 for diabetes still starts with a metformin history.
“Clinical Criteria for GLP-1 Receptor Agonists - History of either metformin or TZD therapy in the past 90 days”
Rhode Island Executive Office of Health and Human Services — Updated: 6/16/2026
Which of these companies serve Rhode Island?
Of the 159 companies we grade, 19 publish a list of the states they are licensed in. We checked 137 more and found no such list on any page we read; 3 we have not checked either way.
9 of those lists name Rhode Island: Gala Health, Care Bare Rx, Vita Bella, TelePeptide, Levity, Wisp, WePeptideRx, TeleClinic and Tyde Wellness. That is a licensure claim each company makes about itself, not something we checked with a state board.
A published list is a starting point, not a guarantee. If availability decides your choice, ask before you pay and get the answer in writing.
Sources
Each document below was fetched and read on the date shown beside it, which is the date printed on the document — not always the date in its web address. All of them were read in September 2026, the same session as the rest of this page.
- Memorandum — Subject: GLP-1 State Budget Guidance — Rhode Island Executive Office of Health and Human Services. the "Date:" line in the memo header: August 5, 2026.
- Rhode Island Medicaid Fee for Service Preferred Drug List — Rhode Island Executive Office of Health and Human Services. the third line of the cover page: Updated: 6/16/2026.
Nothing on this page is medical advice, and nobody here is a clinician. Coverage rules change; check the linked document before you rely on it.
If you're paying cash instead
None of the above changes what a telehealth seller charges you. None of the 3 rows below carries both a medication price and a monthly fee we could capture, so no figure here is a sum. Each cell says what its number covers and what we could not confirm, and every number was read on the seller's own page.
Ro, Alan Meds and WeightWatchers Clinic pay us nothing — none of the 3 below does. The buttons run through our own redirect so we can count the click, and counting is all they do.
| Grade | Provider | What a month actually costs | The one thing that matters here | Go to the provider |
|---|---|---|---|---|
| BMinor gap | Ro | $349a month, medication onlybrand semaglutideMedication only. We captured no separate monthly charge on the pages we read, which is what we found rather than proof that nothing else is billed.Advertised at $199The lowest of the 2 medication prices we captured here | Sells the branded drugs Rhode Island is about to stop paying for. Wegovy is $199 for the first two starter doses and $349 at maintenance, with membership billed separately on top. | See its prices at Ro (opens in a new tab)Pays us nothing |
| BMinor gap | Alan Meds | $315a month, medication onlycompounded semaglutideMedication only. We captured no separate monthly charge on the pages we read, which is what we found rather than proof that nothing else is billed.$158/mo is Alan Meds' own "buy 1 month, get 1 month free" promotional price, published on the same line as the $315 list price — not a hidden or fine-print figure.The lowest of the 2 medication prices we captured here | Publishes a real month-to-month semaglutide price, which is the only kind you can hold against a benefit that ends on a known date. Its tirzepatide figure assumes a six-month prepay. | See its prices at Alan Meds (opens in a new tab)Pays us nothing |
| CCaveat | WeightWatchers Clinic | No month-to-month medication price we could capture, so there is no monthly total to show.What they do bill every month: $74 a month for clinic membership.The review says what else we found. | Leads with $25 a month; the footnote on the same card says that covers two months of a twelve-month plan and then becomes $74. Neither figure includes the drug. | See its prices at WeightWatchers Clinic (opens in a new tab)Pays us nothing |
Our grading method and how we verify a price explain what those letters mean and where these figures came from.